Pharma News
15 Mar 2026 to 21 Mar 2026
Mar 21, 2026
Generic Semaglutide becomes available in India following patent expiration, leading to significant price reductions.
Generic versions of Semaglutide have launched in India following the patent expiry, significantly reducing prices for diabetes and obesity treatments. Major companies like Sun Pharma, Dr Reddy’s Laboratories, Zydus Life Sciences, and Glenmark Pharmaceuticals introduced their products, with monthly costs dropping from ₹8,800-₹11,000 to as low as ₹325-₹4,200, benefiting millions of diabetic patients.
Mar 21, 2026
Price Competition Heats Up in India as Generic Obesity Medications Drive Down Costs
India's obesity treatment market is experiencing a price war following the March 20 patent expiry for Eli Lilly's Mounjaro and Novo Nordisk's semaglutide products. Six generic manufacturers, including Sun Pharma and Natco Pharma, have launched affordable versions, significantly lowering prices. While this increases access, concerns about misuse and regulatory compliance are rising, potentially impacting market dynamics and patient safety.
Mar 21, 2026
Generic Version of Semaglutide Introduced in India Following Patent Expiration - Rediff Money
Torrent Pharmaceuticals, Alkem Laboratories, and USV Ltd have launched generic Semaglutide brands in India following the patent expiry. Torrent introduced Sembolic and Semalix, while Alkem released Semasize, Obesema, and Hepaglide. USV's Usema, developed with Dr Reddy's, targets Type 2 diabetes. These affordable options aim to address India's rising diabetes crisis, affecting over 100 million people.
Mar 21, 2026
Price Competition for Obesity Medications: Indian Firms Create a Stir Following Patent Expiration...
Following the patent expirations of Eli Lilly's Mounjaro and Novo Nordisk's semaglutide drugs, Indian companies like Sun Pharma, Dr. Reddy's Laboratories, and Alkem Laboratories have launched affordable generic versions, drastically reducing prices. While this increases access to obesity treatments, concerns about patient safety and regulatory oversight have also emerged. The market is projected to grow significantly by 2030.
Mar 21, 2026
Semaglutide Price Reduction: Major Shift for Indian Pharmaceutical Companies! - Whalesbook
Indian pharmaceutical companies, including Sun Pharma, Torrent Pharma, and Dr Reddy's, have launched affordable generic versions of semaglutide following the expiration of Novo Nordisk's patent. This price drop makes diabetes and weight loss treatments significantly more accessible, with Sun Pharma offering weekly doses priced between ₹750 and ₹2,000. This move is expected to benefit millions in India facing metabolic disorders.
Mar 21, 2026
Dr. Reddy's Launches Ne Machaya Shor! Generic Semaglutide Sparks Major Price Competition in India
Dr. Reddy's Laboratories has launched its generic semaglutide, Obeda, following the patent expiry of Novo Nordisk's drug, initiating a significant price war in India's GLP-1 therapy market. Priced at ₹4,200 per month, Obeda aims to enhance accessibility for diabetes and weight loss treatments. The company plans to launch 12 million pens in the first year and expand to 87 countries.
Mar 21, 2026
Affordable Ozempic now available: Dr. Reddy's introduces generic semaglutide following patent expiration.
Dr Reddy’s Laboratories has introduced India’s first generic semaglutide injection for Type 2 diabetes, priced at approximately ₹4,200 per month. This launch follows the patent expiry of the original drug and aims to provide a more affordable treatment option, aiding in blood sugar control and weight loss for millions of patients in India.
Mar 21, 2026
India's 'Ozempic' price competition: Generic versions reduce medication prices by 90 percent - Telangana Today
A price war has erupted in India following the patent expiry of Semaglutide, with generics now up to 90% cheaper. NATCO Pharma launched its generic Semanat at Rs 1,290, while Glenmark's Glipiq starts at Rs 325 weekly. Other companies like Sun Pharma and Dr. Reddy’s are also entering the market, significantly increasing access to diabetes and obesity treatments.
Mar 21, 2026
Sun Pharma, Dr. Reddy's, Zydus, and Glenmark launch generic versions of Semaglutide - The Hindu
Sun Pharmaceutical, Dr. Reddy’s Laboratories, Zydus Life Sciences, and Glenmark Pharmaceuticals launched generic versions of Semaglutide in India following the patent expiration of Novo Nordisk's drugs, Wegovy and Ozempic. The generics target a $1 billion market, with Dr. Reddy’s Obeda priced at ₹4,200/month, while Sun's Noveltreat and Sematrinity range from ₹750 to ₹2,000.
Mar 21, 2026
Generic versions of Ozempic available for $14 as the GLP-1 era begins in India - Los Angeles Times
At least a dozen Indian drugmakers, including Natco Pharma Ltd., Sun Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories Ltd., are set to launch generic versions of Novo Nordisk's weight-loss drugs Ozempic and Wegovy, containing semaglutide, following patent expiry. Prices are expected to drop significantly, with Natco's injection starting at 1,290 rupees ($14) monthly, amid a competitive market projected to reach $1 billion.
Mar 21, 2026
Semaglutide Patent Expiration: Increased Availability and Reduced Prices for Affordable Weight Loss Medications
Natco Pharmaceuticals is set to launch its new drugs, Semanat and Semafull, in 2mg, 4mg, and 8mg doses, priced at Rs 1,290 to Rs 1,750 per month. Additionally, the company will introduce an easy-to-inject pen device next month, with prices ranging from Rs 4,000 to Rs 4,500.
Mar 21, 2026
Semaglutide Becomes Available as a Generic in India: More than 40 Pharmaceutical Firms Introduce Weight-Loss Medication
India's pharmaceutical landscape shifts as Novo Nordisk's patent on semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, expires. Over 40 Indian companies plan to launch more than 50 generic versions, reducing monthly costs from Rs 8,800-20,000 to Rs 3,000-5,000. However, concerns about safety, quality, and regulatory oversight remain as the market opens.
Mar 21, 2026
EyePoint files lawsuit against competitor Ocular Therapeutix, claiming misleading statements regarding eye medication - KFGO
EyePoint has filed a lawsuit against Ocular Therapeutix, alleging defamation and false statements regarding EyePoint's lead drug, Duravyu, which is in late-stage trials for wet age-related macular degeneration. EyePoint seeks a court order to stop Ocular's claims, a public retraction, and damages. Ocular's drug, Axpaxli, recently achieved success in a late-stage trial for wet AMD.
Mar 21, 2026
India's breakthrough in affordable weight loss medications could transform the battle against 'dia-besity'.
India is set to see a surge in affordable GLP-1 drugs following the patent expiration of semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy. Seven companies, including Zydus Lifesciences and Sun Pharma, have launched generics priced 65-90% lower. This development aims to improve access for the 101 million diabetics and 254 million obese individuals in the country.
Mar 21, 2026
Alkem Laboratories introduces semaglutide in India priced at Rs 450 weekly, targeting a growing market...
Alkem Laboratories has launched a new semaglutide injection in India, targeting the diabetes and weight loss market. Available under the brand names Semasize and Obesema, the injection is administered weekly. A pre-filled pen for a month's dosage is priced at Rs 1,800, equating to a weekly cost of Rs 450.
Mar 21, 2026
NATCO Pharma Becomes First to Introduce Generic Semaglutide in India, with Prices Starting at Rs 1,290
Novo Nordisk is set to lose its patent in 10 additional countries, including Brazil, China, South Africa, Turkey, and Canada, by the end of 2026.
Mar 21, 2026
Patent Expiration of Semaglutide Sparks Surge of Generic Versions in India | Chemical Industry Digest
The patent expiration for Semaglutide, used in Novo Nordisk's Wegovy and Ozempic, is set to spark competition in the diabetes and obesity treatment market, with 15 to 50 generic versions expected. Companies like Dr. Reddy’s, Sun Pharma, and Eli Lilly are preparing to launch lower-cost alternatives, potentially reducing prices by up to 60%. However, experts caution about safety and regulatory concerns.
Mar 21, 2026
Revolutionary or exaggerated? The effect of weight-loss medications on food consumption in Europe
The global market for GLP-1 drugs, including those from Novo Nordisk and Eli Lilly, reached approximately $70 billion in 2025, driven by diabetes and weight-loss treatments. In the US, about 12% of adults use these drugs, while in Europe, usage is around 2%. However, 50% of users discontinue GLP-1s within a year due to costs or side effects.
Mar 21, 2026
India's surge in weight-loss medications begins with generics priced 50-90% lower | Mint
Following the loss of patent protection for semaglutide in India, major drugmakers like Dr Reddy’s, Sun Pharma, and Zydus Lifesciences have launched generics priced 50-90% lower than innovator brands. This shift is set to expand the GLP-1 market, with prices ranging from ₹1,300 to ₹4,500 monthly, as demand for weight-loss and diabetes treatments surges.
Mar 20, 2026
FDA greenlights a new, stronger dosage of Wegovy injections - WFMJ.com
Mar 20, 2026
Novartis Secures $3 Billion Agreement for Breast Cancer Treatment - TradingView
Novartis (NVS) is acquiring a pan-mutant-selective PI3Kα inhibitor program from Synnovation Therapeutics, featuring lead asset SNV4818, for $2 billion upfront and up to $1 billion in milestones. This acquisition targets HR+/HER2- breast cancer, aiming to enhance tolerability and safety. The deal aligns with Novartis' oncology strategy and is expected to close in the first half of 2026.
Mar 20, 2026
Novo Nordisk Encounters Surge of Generic Competition in India Following Semaglutide Patent Expiration | Whalesbook
Novo Nordisk faces impending competition in India as the patent for its diabetes and weight-loss drug semaglutide expires in 2026, allowing over 40 companies to launch generics. The company is adopting a 'microscope' strategy to monitor pricing and market dynamics amid aggressive competitors like Eli Lilly and Sun Pharmaceuticals, which has already received approval for its generic, Noveltreat.
Mar 20, 2026
FDA Greenlights New High-Dose Wegovy in the US for Enhanced Weight Loss - Science Alert
The FDA has approved a higher-dose version of Novo Nordisk's obesity drug Wegovy, increasing the dosage from 2.4 mg to 7.2 mg. This new formulation, called Wegovy HD, may help users lose more weight, with studies showing a 19% weight loss. However, side effects like nausea and skin sensations were reported in over 70% of users. The drug will be available in April.
Mar 20, 2026
AdAlta obtains Canadian patent, finalizing worldwide coverage for its AD-214 drug targeting fibrosis.
AdAlta Ltd has secured a Canadian patent for its anti-fibrotic drug candidate AD-214, completing global protection across major markets, including the US, EU, and Japan. The patent covers the i-body® sequence and related therapeutic uses for conditions like idiopathic pulmonary fibrosis. AdAlta aims to partner for further development, with potential exclusivity extending to 2043.
Mar 20, 2026
Prices of weight-loss medications drop by 70-90% with the introduction of generics - The Financial Express
Generic versions of Novo Nordisk's semaglutide, sold as Wegovy, will launch in India with discounts of 70-90% following the patent expiration. Companies like Natco Pharma and Eris Lifesciences will offer their versions, enhancing accessibility to GLP-1 therapy for obesity management. Analysts predict a doubling of GLP-1 drug sales in the coming months due to these price cuts.
Mar 20, 2026
GLP-1 Medications Becoming Generic: Implications for Cost, Accessibility, and Safety - The South First
The Indian patent on Semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, expires on March 21, allowing over 40 Indian companies to launch generic versions at reduced prices, potentially cutting costs by 50-60%. While this increases access to diabetes and obesity treatments, experts caution against misuse and emphasize the need for medical supervision.
Mar 20, 2026
India aims to combat worldwide obesity through affordable weight-loss injections.
India is set to launch low-cost generic versions of weight-loss drug semaglutide, found in Ozempic, following the expiration of key patents. This move is expected to significantly increase access to obesity treatments, with projections of sales exceeding $500 million by 2030. Major firms like Zydus Lifesciences are preparing for immediate launches, potentially transforming the market in middle-income countries.
Mar 20, 2026
Prices of weight loss medications will decrease starting tomorrow, with each injection priced at Rs 1290.
India's obesity drug market is set for disruption as over a dozen pharmaceutical companies, including Natco Pharma, Sun Pharma, and Dr. Reddy’s, prepare to launch generic versions of Novo Nordisk’s semaglutide, used in Ozempic and Wegovy, after patent expiration on March 20. This could significantly reduce prices, expanding access to weight-loss treatments in a competitive landscape.
Mar 20, 2026
Novo Nordisk's Wegovy HD receives FDA approval as patents near expiration.
Novo Nordisk has received FDA approval for a high-dose version of its weight loss drug, Wegovy (semaglutide), set to launch in April 2026. The 7.2mg Wegovy HD is designed for patients with obesity and related conditions. This approval comes as Wegovy's patents expire in India and China, prompting interest from multiple manufacturers in producing biosimilars.
Mar 20, 2026
Patent Expiration of Semaglutide Triggers Surge of Generic Versions in India, Leading to Significant Price Reductions
India's diabetes and weight-loss drug market is poised for disruption as Novo Nordisk's patent on semaglutide expires, allowing over 40 local firms, including Sun Pharma and Dr. Reddy's, to launch generics. Prices may drop by 50-60%, expanding access but raising concerns about misuse and regulatory oversight. Analysts predict that doctor confidence will ultimately determine market winners.
Mar 20, 2026
FDA Approves Novo Nordisk's Wegovy HD as Patents Expire - Yahoo Finance
Novo Nordisk has received FDA approval for Wegovy HD, a high-dose version of its weight loss drug Wegovy (semaglutide), set to launch in April 2026. The approval follows the STEP UP trial, showing enhanced weight loss. With Wegovy's patents expiring in India and China, multiple manufacturers, including Natco Pharma, are preparing to introduce biosimilars.
Mar 20, 2026
Varanasi STF Dismantles Counterfeit Drug Operation: 300 Boxes Valued at ₹7.5 Crore Confiscated, Leader Taken into Custody
The Uttar Pradesh Special Task Force (STF) has dismantled a counterfeit drug syndicate in Varanasi, seizing 300 boxes of fake medicines valued at ₹7.5 crore. The operation led to the arrest of the kingpin behind the racket, highlighting ongoing efforts to combat the distribution of counterfeit pharmaceuticals in the region.
Mar 20, 2026
Trade group cautions that conflict in Iran may lead to increased medication costs in the UK - The Jerusalem Post
Britain is facing potential medicine shortages due to rising freight costs linked to the Middle East conflict, warns Medicines UK CEO Mark Samuels. Generic drugmakers, particularly those producing off-patent medicines, are under pressure as transport costs threaten their margins. If instability continues, price increases and supply failures may occur, impacting NHS medicines significantly.
Mar 20, 2026
Novo Nordisk's Patent Ends, Indian Pharmaceutical Companies Prepare to Launch Ozempic-Style Weight Loss Medications
Canada lost patent protection for semaglutide earlier this year, but generic approvals are still pending. India is expected to be the first major market to see a rise in copycat versions, leading to price competition. Novo Nordisk will face similar patent expiries in China, Brazil, and Turkey, prompting global attention on the situation.
Mar 20, 2026
Two Healthcare Stocks to Consider Purchasing Before They Are Acquired - The Globe and Mail
Abivax is considered a potential buyout candidate due to its lead drug obefazimod, currently in phase 3 trials for ulcerative colitis. Meanwhile, Nektar Therapeutics' shares have surged 77% in 2026, driven by positive results for its eczema treatment, rezpegaldesleukin. Both companies are seen as attractive targets for larger pharmaceutical firms amid promising clinical developments.
Mar 20, 2026
India's affordable weight-loss medications set to transform the global battle against obesity - Ghanaian Times
India is set to see a surge in weight-loss drug availability as the patent for semaglutide, the active ingredient in Novo Nordisk's Wegovy and Ozempic, expires. This will enable local companies to produce generics, potentially reducing prices by over 50%. Analysts predict the semaglutide market could reach $1 billion in India, with around 50 generics expected soon.
Mar 20, 2026
THE IMPACT OF A BLOCKBUSTER DRUG EXPIRING ITS PATENT | CNBC-TV18
As key patents for Ozempic, a drug originally designed for diabetes treatment, expire, the future of its weight loss impact is uncertain. The drug, containing semaglutide, has significantly influenced obesity treatment, raising questions about market dynamics and competition in the wake of patent loss.
Mar 20, 2026
Generic versions of Ozempic expected to drop to $14 in India as the GLP-1 era begins - Business Standard
As Novo Nordisk's patent for semaglutide expires, at least a dozen Indian drugmakers, including Natco Pharma, Sun Pharmaceutical, and Dr. Reddy’s, are set to launch generic versions of the weight-loss drugs Ozempic and Wegovy. Prices are expected to drop significantly, with Natco's injection starting at ₹1,290 ($14) monthly, igniting a competitive market for anti-obesity therapies.
Mar 20, 2026
The patent for Semaglutide is set to expire today. What implications does this have for patients, pharmaceutical companies, and others?
Semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, has gone off patent, allowing Indian companies like Sun Pharma, Dr Reddy’s, and Lupin to launch generics starting March 21. Prices are expected to drop by 50-70%, improving access for diabetic and obese patients. Novo Nordisk plans to defend its market share through collaborations and price reductions.
Mar 20, 2026
Exploring Weight Loss Medications? Anticipate a Surge of New Choices - KFF Health News
The FDA has approved a higher dose of Novo Nordisk's Wegovy weight-loss medication, while Eli Lilly's experimental drug, retatrutide, has shown record weight loss in diabetic patients. Additionally, Ozempic and Wegovy are set to go generic in Canada, India, and China, making these treatments more accessible.
Mar 20, 2026
Rupee falls below 93, new tax regulations introduced, and a popular medication set to become more affordable - LinkedIn
The patent for the weight-loss drug Semaglutide has expired, allowing Indian drugmakers like Sun Pharma, Dr Reddy’s, Zydus, and Mankind to introduce branded generics. This could reduce medicine prices by 50-70%, improving access for millions of diabetic and obese patients, according to Vishwanath Pilla's report.
Mar 20, 2026
Cost of weight-loss medications in India set to decrease starting March 21 - Dailymotion video
The patent for semaglutide, the active ingredient in weight loss drugs like Ozempic and Wegovy, has expired, leading to a significant price drop in India. Starting March 21, generics will flood the market, reducing costs from 9,000-28,000 rupees to as low as 3,000-4,000 rupees monthly. However, these drugs should only be prescribed by specialists for clinically obese patients.
Mar 19, 2026
Ozempic will soon have generic versions available for as little as $15 — implications for Americans explained.
India is set to launch generic versions of Ozempic and Wegovy this weekend, as Novo Nordisk's patent on semaglutide expires. This move is expected to significantly reduce prices, potentially by 50-60%. Other countries, including China and Brazil, will follow suit. However, U.S. consumers will have to wait until 2032 for generics due to existing patents.
Mar 19, 2026
Reasons for Doctors' Enthusiasm Over Icotyde, a Novel Pill for Psoriasis - Everyday Health
The FDA has approved Icotyde (icotrokinra), the first oral interleukin-23 receptor antagonist for moderate to severe plaque psoriasis, providing an alternative to injectable treatments like Skyrizi and Tremfya. In clinical trials, 70% of patients achieved clear skin after 16 weeks. Johnson & Johnson manufactures Icotyde, but pricing and availability details are yet to be announced.
Mar 19, 2026
FDA Greenlights Enhanced Dosage of Wegovy Injections
The FDA has approved a higher-dose version of Novo Nordisk's obesity drug Wegovy, increasing the dosage from 2.4 mg to 7.2 mg. This new formulation, expected to be available in April, may help users achieve greater weight loss. However, it is associated with higher rates of side effects, including nausea and skin sensations.
Mar 19, 2026
Lilly's new medication demonstrates notable improvements in blood sugar levels and weight loss during diabetes research - KFGO
Eli Lilly's next-generation obesity drug, retatrutide, demonstrated significant reductions in blood sugar and weight in a late-stage trial, outperforming its previous drugs. The trial showed an average weight loss of 15.3% and a reduction in A1C levels by 1.7% to 2.0%. Analysts predict a 2027 launch with potential annual sales of $4.9 billion by 2030.
Mar 19, 2026
Novo's High Dose Wegovy Receives Fourth Approval from FDA's National Priority Voucher Program
The FDA has approved a higher 7.2 mg dose of Novo Nordisk’s semaglutide, branded as Wegovy HD, for weight loss, marking the fourth approval under the Commissioner’s National Priority Voucher program. The launch is set for April 2026, with clinical trials showing significant weight loss benefits. Wegovy HD is the first GLP-1 treatment approved under this expedited program.
Mar 19, 2026
US FDA grants approval for an increased dosage of Novo's Wegovy through a new expedited review process.
Novo Nordisk announced FDA approval for a higher 7.2-milligram dose of its weight-loss drug Wegovy, aimed at enhancing its market position amid competition from Eli Lilly. The new dose, which showed significant weight loss in trials, will launch in the U.S. in April. The UK and EU have already approved it for separate injections.
Mar 19, 2026
FDA greenlights a new, stronger dosage of Wegovy injections.
The FDA has approved a higher-dose version of Novo Nordisk's obesity drug Wegovy, increasing the dosage from 2.4 mg to 7.2 mg. This new formulation, called Wegovy HD, may enhance weight loss, with study participants losing about 19% of body weight. The drug will be available in April, with pricing to be announced. Side effects were reported in over 70% of users.
Mar 19, 2026
Johnson & Johnson Receives USFDA Approval for Oral Psoriasis Medication Icotyde - Medical Dialogues
The U.S. FDA has approved Johnson & Johnson's oral pill, Icotyde, for moderate-to-severe plaque psoriasis, offering a convenient treatment option for patients. This drug, developed with Protagonist Therapeutics, aims to compete with Bristol Myers Squibb's Sotyktu and AbbVie's Skyrizi. Analysts predict Icotyde has "blockbuster potential" due to its safety and effectiveness.
Mar 19, 2026
Could the blood of pythons be the solution for a new weight-loss medication? - The Times
Researchers at the University of Colorado Boulder have discovered an appetite-suppressing molecule, para-tyramine-O-sulfate (pTOS), in python blood that could lead to new weight-loss drugs. Unlike GLP-1 drugs like Ozempic, Wegovy, and Mounjaro, pTOS reduces food intake without muscle loss or nausea. A start-up, Arkana Therapeutics, aims to develop synthetic versions for therapeutic use.
Mar 19, 2026
India's affordable weight-loss medications may transform the global battle against obesity - MyJoyOnline
India is set to see a surge in affordable weight-loss drugs as the patent for semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, expires. Major Indian firms like Cipla and Sun Pharma are preparing to launch generics, potentially reducing prices from up to $173 to around $36-$54 monthly. This could significantly expand access for millions battling obesity and diabetes.
Mar 19, 2026
Ozempic is set to become available in generic form for millions of individuals.
Novo Nordisk's weight loss drugs, Ozempic and Wegovy, are set to lose patent protection in several populous countries, including India and China, allowing for cheaper generics. This shift could democratize access to semaglutide, benefiting millions with obesity and diabetes. Generic versions are expected soon, while Novo Nordisk faces increased competition and potential market share loss.
Mar 19, 2026
Lilly's new obesity medication demonstrates decreased blood sugar levels in clinical trial.
Eli Lilly's next-generation obesity drug, retatrutide, demonstrated significant reductions in blood sugar and weight in a late-stage trial, outperforming its previous drugs. The trial showed an average weight loss of 15.3% and a reduction in A1C levels by 1.7% to 2.0%. Analysts predict a 2027 launch with potential annual sales of $4.9 billion by 2030.
Mar 19, 2026
AdAlta Obtains Canadian Patent for AD-214, an Anti-Fibrotic Medication | Finance News Network
AdAlta Limited (ASX:1AD) has secured a new composition of matter patent in Canada for its anti-fibrotic product, AD-214, which targets Idiopathic Pulmonary Fibrosis (IPF) and kidney fibrosis. The patent, protecting the i-body® sequence, expires on January 8, 2036. AdAlta has also applied for additional patents related to dosing and treatment methods, potentially extending protection until 2043.
Mar 19, 2026
Global business updates | Patent expiration of Novo Nordisk's weight-loss medications to advantage India
India's diabetes and weight-loss drug market is poised for disruption as Novo Nordisk's patent on semaglutide expires, leading to over 40 Indian firms launching more than 50 generic brands. While this increases access in a price-sensitive market, concerns about oversight and potential misuse arise as costs significantly decrease.
Mar 19, 2026
India initiates a price competition for weight-loss treatments following the expiration of the semaglutide patent.
Namita Joshi, a 29-year-old interior designer from Mumbai, has lost 6kg in two months using weekly weight-loss injections, despite the high cost of 30,000 Indian rupees (US$322) monthly. She hopes the investment will improve her mental health and dating life, although she experiences nausea as a side effect. Prices for these medications are expected to decrease further.
Mar 18, 2026
AIM ImmunoTech Receives Final Authorization for Innovative Cancer Treatment Patent in Japan
AIM ImmunoTech Inc. announced the approval of a Japanese patent for Ampligen (rintatolimod) in combination with checkpoint inhibitors for cancer treatment. This patent, which covers various cancer types including pancreatic cancer, is part of AIM's strategy to address unmet health needs. The company also seeks orphan drug designation in Japan for Ampligen.
Mar 18, 2026
FTC is observing the responses of pharmaceutical companies to the impending patent expiration, according to an official - AOL.com
The U.S. Federal Trade Commission (FTC), led by Dan Guarnera, is intensifying scrutiny of anticompetitive practices in the pharmaceutical sector as key drugs like Merck's Keytruda and Bristol Myers Squibb's Eliquis approach patent expirations. The FTC aims to ensure fair pricing and innovation, recently blocking a $356 million merger between Alcon and Lensar to maintain competition in cataract surgery technologies.
Mar 18, 2026
India poised to transform the weight-loss medication industry with the expiration of semaglutide's patent.
The patent for semaglutide, the active ingredient in Novo Nordisk's drugs Wegovy and Ozempic, is set to expire in India, paving the way for cheaper generics. Major Indian companies like Cipla and Sun Pharma are preparing to launch alternatives, potentially reducing treatment costs from $95-$173 to $36-$54. This shift could significantly impact India's $1 billion semaglutide market.
Mar 18, 2026
CILFA's stance regarding pharmaceutical patents in Argentina - Pharmabiz.NET
Argentina's government has established new pharmaceutical patent criteria, prompting criticism from CILFA, the chamber representing local drugmakers. CILFA opposes the repeal of 2012 patentability guidelines, citing concerns over evergreening patents that hinder competition. They highlight the success of generic and biosimilar drugs, including rituximab and Keytruda, which have significantly reduced costs and improved patient access.
Mar 18, 2026
Johnson & Johnson's $32 Billion Acquisition of Intra-Cellular Therapies Transforms CNS Pharmaceuticals
Johnson & Johnson's acquisition of Intra-Cellular Therapies for $32 billion in 2025 enhances its neuroscience portfolio, particularly with the drug Caplyta, approved for bipolar disorder and schizophrenia. This strategic move raises questions for European investors regarding Caplyta's rollout and integration risks, while positioning J&J for robust growth in the CNS market amid ongoing sector volatility.
Mar 18, 2026
Affordable weight-loss medications from India may transform the global battle against obesity - Capital FM
The patent for semaglutide, the active ingredient in Novo Nordisk's weight-loss drugs Wegovy and Ozempic, expires in India, paving the way for generics. Analysts predict up to 50 branded generics could enter the market, potentially reducing prices by over half. This shift could expand access to effective weight-loss treatments for India's large diabetic and obese population.
Mar 18, 2026
From Diabetes Management to Weight Loss: The Rise of Semaglutide as a Major Success - NDTV
Semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, is set to transform obesity treatment as key patents expire, allowing generics to enter markets like India. Originally developed for type 2 diabetes, semaglutide's weight-loss benefits have garnered global attention, but affordability remains a concern. The upcoming generics could enhance access and reshape healthcare for millions.
Mar 18, 2026
Semaglutide approaches patent expiration in two days: India prepares for launch of over 50 brands.
India's pharmaceutical market is set for a major transformation as the patent on semaglutide, the active ingredient in Ozempic and Wegovy, expires on March 20. Over 50 generic versions are expected, significantly reducing prices from Rs 8,800-16,400 to Rs 3,000-4,000 monthly. This shift could democratize access to diabetes and obesity treatments, with companies like Sun Pharma and Dr Reddy’s leading the charge.
Mar 18, 2026
Are affordable anti-obesity medications on the verge of arriving in India? - Firstpost
The patent on Semaglutide, a key ingredient in weight-loss drugs, expires on March 20, paving the way for cheaper generic anti-obesity medications in India. Pharma companies like Zydus, Torrent Pharma, Sun Pharma, and Dr. Reddy’s Laboratories are preparing to launch affordable versions, potentially reducing costs by 50-80%. However, concerns remain about accessibility and coverage under public health schemes.
Mar 18, 2026
FDA Gives Green Light to Johnson & Johnson's Oral Medication for Psoriasis
The FDA has approved Johnson & Johnson's oral psoriasis treatment, Icotyde, for moderate-to-severe plaque psoriasis in patients aged 12 and older. This first-of-its-kind pill, developed with Protagonist Therapeutics, could generate over $8 billion in annual sales and is expected to become a first-line therapy, competing with Bristol Myers Squibb’s Sotyktu and AbbVie’s Skyrizi.
Mar 18, 2026
AIM ImmunoTech obtains cancer patent for Ampligen in Japan - Stock Titan
AIM ImmunoTech Inc. has received final approval for a Japanese patent covering the use of Ampligen (rintatolimod) in combination with checkpoint inhibitors for cancer treatment. The company plans to pursue Orphan Drug Designation for Ampligen in pancreatic cancer, addressing a significant health challenge. AIM also holds related patents in the U.S. and the Netherlands.
Mar 18, 2026
FTC Increases Antitrust Scrutiny on Pharmaceutical Industry as Major Drug Patents Near Expiration
The U.S. Federal Trade Commission (FTC) is scrutinizing anticompetitive practices in the pharmaceutical industry as key drugs like Merck's Keytruda, Bristol Myers Squibb and Pfizer's Eliquis, and J&J's Darzalex approach patent expirations. FTC's Dan Guarnera emphasized the agency's commitment to ensuring fair market conditions and innovation, while also blocking a $356 million merger in the healthcare sector.
Mar 18, 2026
India's affordable weight-loss medications, Ozempic and Wegovy, may transform the global battle against obesity - BBC
India's pharmaceutical industry, valued at approximately $60 billion, is projected to double by 2030, driven by generics. This growth sets the stage for increased competition over semaglutide, an expensive injection that may soon become more accessible to a broader patient base.
Mar 18, 2026
India is set to welcome 50 generic versions of Wegovy - Altitudes Magazine
The patent for semaglutide, the active ingredient in Novo Nordisk's weight-loss drugs Ozempic and Wegovy, expires in India this Friday. This could lead to the introduction of around 50 generics, significantly reducing prices and increasing access for millions. Analysts predict the Indian semaglutide market could reach $1 billion, potentially reshaping global obesity treatment.
Mar 18, 2026
J&J vs. Merck: Important Considerations for Investors at This Time - TradingView
Johnson & Johnson (JNJ) and Merck (MRK) are compared as leading U.S. healthcare companies. JNJ shows strong growth in its diversified portfolio, particularly in oncology and medical devices, while MRK relies heavily on its blockbuster drug Keytruda. Both face challenges from patent expirations and market pressures, but JNJ is projected to outperform MRK in 2026 with a bullish revenue outlook.
Mar 18, 2026
Pharmaceutical Sector Confronts Growing Legal Challenges and Upcoming Patent Expirations on ...
The pharmaceutical industry is facing increasing lawsuits over patent infringements and product liability, alongside approaching patent expirations on blockbuster drugs. These challenges could significantly impact revenue for major companies as generic competitors enter the market. Analysts are observing how firms will navigate these issues through innovation and strategic partnerships.
Mar 18, 2026
FDA grants approval for Johnson & Johnson's oral medication for psoriasis - ET Pharma
The U.S. FDA has approved Johnson & Johnson's oral psoriasis pill, Icotyde, aimed at treating moderate-to-severe plaque psoriasis in adults and children. This approval allows J&J to compete with Bristol Myers Squibb's Sotyktu and AbbVie's Skyrizi. Analysts predict Icotyde has "blockbuster potential" due to its safety and effectiveness. The drug is also being studied for other conditions.
Mar 17, 2026
Pfizer Encounters Opportunities and Challenges During Transition | Intellectia.AI
Argus has upgraded Pfizer to a Buy rating from Hold, setting a price target of $35. The firm is optimistic about Pfizer's GLP-1 pipeline and its strong oncology and hematology programs, expressing increased confidence in the company's growth potential beyond 2028 due to accelerated R&D and successful product launches.
Mar 17, 2026
Celgene Confronts Key Challenge with Upcoming Patent Expirations - Ad-hoc-news.de
Celgene is navigating significant challenges as its blockbuster drugs face patent expirations, leading to increased competition from generics like pomalidomid. The company is focusing on novel protein degraders in late-stage trials to sustain its market leadership in the immunomodulator segment. Upcoming quarterly reports will reveal the impact of these developments on Celgene's revenue and market position.
Mar 17, 2026
The expiration of the patent will allow for the introduction of Semaglutide generics at prices that are 25% of the current rates.
On March 20, the patent for Semaglutide will expire, allowing seven Indian pharma companies, including Sun Pharma and Dr Reddy’s Labs, to launch generics at significantly reduced prices. Monthly costs are expected to drop from Rs 10,000-12,000 to Rs 3,000-4,000. Zydus Lifesciences and Lupin have partnered to market Semaglutide with an innovative delivery system, enhancing patient access and adherence.
Mar 17, 2026
Boomray announces peptide-drug conjugates aimed at FAP - BioWorld
Boomray Co. Ltd. has developed new peptide-drug conjugates that combine a radionuclide-labeled probe with a fibroblast activation protein α (FAP)-targeting peptide. These conjugates show promise for diagnosing and treating cancer, inflammation, atherosclerosis, fibrosis, and scars.
Mar 17, 2026
Pharmacokinetics: Understanding Its Principles Beyond Natural Laws | Insights - Holland & Knight
A U.S. District Court ruling upheld Astellas Pharma's patents for Myrbetriq® (mirabegron) against Ascent Pharmaceuticals' challenge. The court found that the patents, covering specific sustained-release formulations and treatment methods for overactive bladder, were not invalid under Section 101. Ascent's generic version will be delayed as the patents were deemed patent-eligible and infringed.
Mar 17, 2026
Indian Court Issues Ruling on Novartis Drug Patent Following 15-Year Wait - Whalesbook
The Delhi High Court criticized India's patent office for a 15-year delay in deciding Novartis AG's patent application for Ribociclib, a breast cancer drug. Justice Jyoti Singh ordered resolution within four months, emphasizing the need for efficient intellectual property processes. The delay raises concerns about market exclusivity and investor confidence in Novartis, which holds over 60% of the Ribociclib market share.
Mar 17, 2026
FTC Antitrust Director Discusses Examination of Pharmaceutical Industry as Major Patents Approach Expiration - IndexBox
The U.S. Federal Trade Commission (FTC) is closely monitoring anticompetitive practices in the pharmaceutical sector as key patents near expiration. The FTC's antitrust chief emphasized the importance of ensuring generic drug entry and evaluating mergers' impacts on innovation and drug development. The agency remains focused on healthcare, having previously blocked certain transactions to prevent increased costs and reduced innovation.
Mar 17, 2026
Analyst suggests US reshoring efforts may negatively impact China's contract pharmaceutical manufacturers - SCMP
Chinese contract drug makers, including WuXi AppTec, WuXi Biologics, and WuXi XDC, face uncertain long-term revenue as US firms shift production in-house amid rising tensions. Jefferies' Cui Cui noted strong earnings visibility for 2026-2027 but limited clarity on future growth. US scrutiny of Chinese biotech firms has increased, yet interest in partnerships remains.
Mar 17, 2026
Assessing the 2026 Orphan Drug Report - PharmiWeb.com
A new report by Evaluate reveals that orphan drugs will account for over 21% of prescription pharmaceuticals by 2032, generating over $400 billion in sales. Johnson & Johnson's Darzalex is projected to be the top-selling orphan drug, with nearly $31 billion in sales. Despite challenges, orphan drugs remain resilient in the evolving pharma landscape.
Mar 17, 2026
Indian Pharmaceutical Companies Set to Introduce Generic Semaglutide Following Ozempic Patent Expiration
The patent for semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, will expire in India on March 20, 2026, allowing Indian companies like Sun Pharmaceutical, Zydus Lifesciences, and Lupin to launch generics. This shift is expected to enhance access to diabetes and obesity treatments, reshaping the market and increasing competition for GLP-1 therapies.
Mar 17, 2026
Novo Nordisk dismisses the possibility of a price war with the introduction of semaglutide generics in India - Business Standard
Novo Nordisk's semaglutide patent is set to expire in India, allowing generic competitors like Sun Pharmaceutical, Zydus Lifesciences, and Dr Reddy’s Laboratories to enter the market. Despite anticipated price drops of 60-70%, Novo Nordisk aims to focus on scientific quality and expanding the obesity treatment market, emphasizing the need for increased patient access and awareness.
Mar 17, 2026
Can Bristol Myers Squibb's pipeline approach mitigate the impact of a significant patent expiration? - Labiotech.eu
Bristol Myers Squibb is navigating a significant patent cliff, reshaping its pipeline strategy through R&D and acquisitions. Key drugs like Revlimid and Pomalyst face generic competition, while the company focuses on oncology, immunology, and neuroscience, highlighted by the $14 billion acquisition of Karuna Therapeutics and the antipsychotic Cobenfy. Future growth hinges on new therapies to offset declining legacy revenues.
Mar 17, 2026
Experts recommend that public health plans should include coverage for generic versions of weight-loss medications once they become available.
Obesity experts advocate for public health plans to cover GLP-1 medications like Ozempic and Wegovy, as many Canadians face financial barriers to access. With generics of semaglutide expected soon, experts believe universal coverage is inevitable, potentially reducing healthcare costs. Current coverage is limited, primarily for Type 2 diabetes, leaving many without support for weight management.
Mar 17, 2026
AstraZeneca's Imfinzi Receives EU Approval for Gastric Cancer Treatment - TradingView
AstraZeneca's Imfinzi (durvalumab) has received European Commission approval as the first perioperative treatment for early gastric and gastroesophageal junction cancers, in combination with FLOT chemotherapy. This decision follows positive results from the Phase III MATTERHORN study, showing significant survival benefits. Imfinzi is already approved in the U.S. and is a key revenue driver for AstraZeneca, generating $6.1 billion in sales.
Mar 16, 2026
India prepares for more affordable anti-obesity medications following the expiration of Ozempic's patent - ThePrint
India is set to see a surge in obesity-focused services as the patent for Novo Nordisk's semaglutide, the active ingredient in Ozempic and Wegovy, expires on March 20. Five Indian drugmakers, including Dr. Reddy’s Laboratories and Mankind Pharma, plan to launch generic versions at half the price, potentially expanding the GLP-1 market from 10 billion to 50 billion rupees by 2030.
Mar 16, 2026
Palvella Therapeutics Reveals Granting of European Patent for Anhydrous...
Palvella Therapeutics has secured European Patent No. 3565520 for its lead product candidate, QTORIN™ rapamycin, extending patent protection until 2038. This anhydrous gel formulation targets serious, rare skin diseases, including microcystic lymphatic malformations, for which there are currently no FDA-approved therapies. QTORIN™ rapamycin has also received European Orphan Drug Designation, potentially granting 10 years of market exclusivity upon approval.
Mar 16, 2026
Affordable Generic Ozempic Set to Arrive in India: Patent Expiration Triggers Surge in Weight-Loss Medications - NDTV
India is set to see a surge in obesity treatments as local drugmakers prepare to launch off-patent versions of Novo Nordisk's semaglutide, the active ingredient in Ozempic and Wegovy, after its patent expires on March 20. Companies like Mankind Pharma, Ajanta Pharma, and Sun Pharmaceutical are expected to offer these generics at half the price, prompting increased demand for obesity management services across the country.
Mar 16, 2026
SciSparc's division supports Hong Kong patent for MDD treatment | SPRC Stock Update
SciSparc Ltd. announced a collaboration between its subsidiary NeuroThera Labs Inc. and Clearmind Medicine Inc. to file a patent for a novel depression therapy combining Clearmind's 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA). This non-hallucinogenic treatment aims to provide a safer, more accessible alternative to traditional antidepressants, potentially benefiting over 332 million people globally.
Mar 16, 2026
SciSparc Partners with NeuroThera Labs and Clearmind Medicine - GlobeNewswire
SciSparc Ltd. announced that its majority-owned subsidiary, NeuroThera Labs Inc., has collaborated with Clearmind Medicine Inc. to file a patent for a novel combination therapy targeting major depressive disorder. The treatment combines Clearmind’s 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), aiming to offer a safer, non-hallucinogenic alternative to traditional antidepressants.
Mar 16, 2026
Producers of generic medications are gearing up to introduce cost-effective alternatives following the expiration of Novo's patent for ... - Mint
Indian pharmaceutical companies, including Ajanta Pharma, Dr Reddy's Laboratories, Lupin, Mankind Pharma, and Sun Pharmaceuticals, are set to launch affordable generic versions of semaglutide after Novo Nordisk's patent expires on March 20. Over 50 brands are expected to enter the market, with prices projected to drop by 40-50%, enhancing obesity management services across healthcare facilities.
Mar 16, 2026
SciSparc and NeuroThera Labs Partner with Clearmind Medicine to Secure Patent ... - Finviz
SciSparc Ltd. announced that its majority-owned subsidiary, NeuroThera Labs Inc., has collaborated with Clearmind Medicine Inc. to file a patent for a novel combination therapy targeting major depressive disorder. The treatment combines Clearmind’s 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), aiming to offer a safer, non-hallucinogenic alternative to traditional antidepressants.
Mar 16, 2026
Patent Expiration for Semaglutide in India May Lead to 50% Reduction in Weight-Loss Medication Prices
India's obesity-drug market is poised for change as Novo Nordisk's semaglutide patent expires on March 20, allowing companies like Mankind Pharma, Ajanta Pharma, and Dr. Reddy's Laboratories to introduce cheaper alternatives. These generics could be 50% less expensive, expanding access to weight-loss medications. Healthcare providers are preparing for increased demand with new clinics and programs, while the GLP-1 market may grow significantly by 2030.
Mar 16, 2026
FDA Takes Steps to Simplify Biosimilar Development: What This Means for Regulatory and Intellectual Property Approaches
The FDA has updated its biosimilar guidance, eliminating the requirement for a three-way pharmacokinetic bridging study, which could reduce development costs by up to 50%. This change aims to facilitate faster market entry for biosimilars, enhancing competition as many blockbuster drug patents expire. The new framework encourages the use of foreign comparator products, aligning U.S. regulations with international standards.
Mar 16, 2026
Top Selections: Biotech focuses on cystic fibrosis research and treatments for rare diseases
Ritu Baral, managing director at TD Cowen, highlighted three biotech companies poised for growth: Sionna Therapeutics, focusing on cystic fibrosis treatments; Praxis Precision Medicines, with its ulixacaltamide for essential tremor; and Palvella Therapeutics, which recently secured a European patent for its skin disease treatment. Investors are optimistic as clinical trial data and regulatory approvals approach.
Mar 16, 2026
Novo Nordisk, the company behind Ozempic and Wegovy, plans to broaden its clinical trials for weight loss injections in children.
Novo Nordisk has partnered with the Murdoch Children’s Research Institute to explore obesity care for adolescents in Pacific Island nations, starting in Fiji. The collaboration aims to address rising obesity rates, with drugs like Ozempic and Wegovy playing a crucial role. CEO Mike Doustdar emphasized the need for broader access and preventive measures against childhood obesity, calling it a "ticking bomb.
Mar 16, 2026
Over 50 Generic Versions of Semaglutide Set to Launch in India Following Patent Expiration for Diabetes Medication in March 2026
The patent for semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, will expire in India on March 20, 2026. This is expected to lead to over 50 branded generics entering the market, significantly reducing treatment costs for diabetes and obesity. Indian companies like Dr Reddy's and Sun Pharma are preparing to launch affordable alternatives, enhancing patient access.
Mar 16, 2026
PFE or BMY: Which Major Cancer Treatment Company Is the Superior Choice at This Time? - TradingView
Pfizer (PFE) and Bristol Myers Squibb (BMY) dominate the oncology market, with PFE's oncology sales constituting 27% of its revenue. PFE's portfolio includes Ibrance and Padcev, bolstered by the acquisition of Seagen. BMY's key drug, Opdivo, has expanded with a new formulation. Analysts suggest PFE is currently a more attractive investment due to its diverse portfolio and valuation.
Mar 16, 2026
Novartis AG initiates a $12 billion stock repurchase following FDA approval and advancements in its pipeline.
Novartis AG has launched a share repurchase program targeting up to 10% of its shares over three years and received FDA approval for Cosentyx to treat adolescents with hidradenitis suppurativa. This comes as the company faces significant patent expiries, particularly for Entresto, its cardiovascular drug. The announcements reflect Novartis' strategy to bolster growth amid revenue challenges.
Mar 16, 2026
Will Merck's Latest Medications and Development Pipeline Alleviate Concerns Over Keytruda's Loss of Exclusivity? - The Globe and Mail
Merck (MRK) is preparing for long-term growth as its PD-1 inhibitor, Keytruda, approaches patent expiration in 2028. Keytruda, which generated $31.7 billion in sales in 2025, is expected to peak at $35 billion before losing exclusivity. Merck's pipeline includes promising products like Capvaxive and Winrevair, with projected commercial opportunities exceeding $70 billion by the mid-2030s.
Mar 16, 2026
Amgen Inc. Shares Remain Steady Around $366 as the Biotech Leader Aims for 12...
Amgen Inc. (ISIN: US0311621009) demonstrates resilience amid market volatility, projecting 2026 revenues of $37.85 billion, driven by strong oncology and cardiovascular drug sales. The stock closed at $366.21, up 12% year-to-date, appealing to risk-averse investors. With a dividend yield of 3.19%, Amgen remains a solid choice for European investors seeking stability in healthcare.
Mar 15, 2026
CareEdge predicts the weight-loss medication market will reach Rs 5000 crore by 2030 - Business News
The weight-loss drugs market in India is projected to grow to Rs 5,000 crore by 2030, driven by the patent expiry of Novo Nordisk’s Semaglutide. Price reductions of up to 50% are expected by FY2027 due to competition. Generic versions from companies like Sun Pharma and Dr Reddy’s Labs are set to launch post-expiry, despite safety concerns and manufacturing challenges.
Mar 15, 2026
Participants in Nigeria's healthcare industry have introduced a mobile application designed to monitor counterfeit antibiotics.
Stakeholders in Nigeria's health sector have introduced the Community Access to Effective Antibiotics (COM-WATCH) mobile app to combat the spread of fake antibiotics and enhance access to authentic medications in underserved areas. The initiative is supported by the Nigeria Centre for Disease Control (NCDC) and the National Agency for Food and Drug Administration and Control (NAFDAC).
Mar 15, 2026
More than 20,000 narcotic tablets, along with thousands of capsules and injections, confiscated in Bihar, Uttar Pradesh, and Punjab.
Authorities have dismantled a multi-state drug racket near the Nepal border, seizing over 20,000 narcotic tablets, thousands of capsules, and injections in Bihar, Uttar Pradesh, and Punjab. The coordinated raids targeted the distribution of misused drugs, including banned cough syrups, highlighting ongoing efforts to combat drug trafficking in the region.
Mar 15, 2026
US1078421011 Encounters Challenges from Biosimilars Amidst Oncology Patent Expiration - Ad-hoc-news.de
Bristol-Myers Squibb (BMS) faces significant revenue challenges in 2026 due to impending biosimilar competition for its key drugs, Keytruda and Opdivo. The company is focusing on its robust R&D pipeline and potential M&A to offset losses. European investors should closely monitor BMS's performance amid pricing pressures and the impact of the patent cliff on its financial outlook.
Mar 15, 2026
J&K&L High Court Dismisses Drug Case Due to Expired Sample Shelf Life, States Accused's...
The J&K High Court has quashed a drugs case against the Managing Director of a pharmaceutical company, emphasizing that the expiration of the drug sample's shelf life infringes on the accused's right to seek re-analysis. This ruling highlights the importance of statutory protections in drug quality prosecutions under the Drugs and Cosmetics Act.
Mar 15, 2026
OICCI expresses disagreement with amendments to the patents ordinance - Business - DAWN.COM
The Overseas Investors Chamber of Commerce and Industry (OICCI) has raised concerns over a proposed amendment to Section 30(3) of the Patents Ordinance 2000 in Pakistan. The amendment could weaken patent enforcement, hinder innovation, and discourage foreign investment by removing legal actions against potential patent infringements, particularly affecting the availability of patented medicines.
Mar 15, 2026
Increased Regulatory Oversight for Novo Nordisk Regarding Medication Safety Reporting
The FDA has mandated Novo Nordisk to submit a corrective action plan after an inspection revealed serious flaws in adverse event reporting for its semaglutide drugs, Ozempic and Wegovy. The company faces increased scrutiny amid a significant stock decline, with shares dropping over 50% in the past year. Novo Nordisk is working to improve its reporting procedures.
Mar 15, 2026
Key Insights on the Potential of GLP-1 Medications in Combating Addiction - Lee News Central
A new study published in the BMJ reveals that GLP-1 drugs, including Ozempic and Mounjaro, may help prevent substance use disorders among diabetes patients. Analyzing over 600,000 U.S. Veterans Affairs patients, researchers found those on GLP-1 medications had lower addiction rates and reduced risks of hospitalization, overdose, and death, suggesting these drugs may address the root causes of cravings.
Mar 15, 2026
Delhi Police Dismantles Interstate Drug Trafficking Network, Arrests Four Suppliers
Delhi Police's Crime Branch has dismantled a significant interstate psychotropic drug supply network involving Delhi, Uttar Pradesh, and Punjab. Four suppliers were arrested during the operation, highlighting ongoing efforts to combat drug trafficking in the region.
Mar 15, 2026
India's struggle against evergreening: The year 2026 could put the drug patent system to the test - Business Standard
Novo Nordisk's patent on semaglutide, the active ingredient in weight-loss drugs like Rybelsus, Ozempic, and Wegovy, expires in India and Canada on March 20, 2026. Indian courts are increasingly challenging patent evergreening, allowing generics like Natco Pharma's Risdiplam and Zydus Lifesciences' Nivolumab to enter the market, potentially reshaping access to affordable medications.
